Đánh giá kết quả điều trị và tác dụng không mong muốn của phác đồ Pembrolizumab kết hợp hóa trị trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IV tại Bệnh viện Phổi Trung ương

Evaluate treatment results and safety of Pembrolizumab combined with chemotherapy in the treatment of stage IV non-small cell lung cancer. Methods: Cross-sectional descriptive study combined with retrospective with longitudinal follow-up on 63 patients with stage IV non-small cell lung cancer treated with Pembrolizumab combined with chemotherapy at the National Lung Hospital. Implementation period is from June 2019 to June 2023. Results: The average age of the patients was 61.95 years old, the male/female gender ratio was 3.5/1. The disease control rate was 84.1%, of which the complete response rate was 3.2%, partial response rate was 68.9% and stability rate was 11.1%. During the treatment process, the patient experienced side effects on the hematopoietic system and outside the hematopoietic system, but at a mild level (grade 1, 2). Patients can recover and continue maintenance treatment until the end of the treatment course. Conclusion: Stage IV non-small cell lung cancer patients treated with Pembrolizumab combined with chemotherapy have high disease control rates and acceptable safety.